- Home
- BHK vs PHAR Comparison
BHK vs PHAR Comparison
Compare BHK & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BHK | PHAR |
|---|---|---|
| Founded | 2001 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 687.6M | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BHK | PHAR |
|---|---|---|
| Price | $9.62 | $16.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 188.3K | 27.8K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 8.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.03 | 0.00 |
| Revenue | N/A | ★ $362,274,000.00 |
| Revenue This Year | N/A | $25.19 |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | ★ $10.42 | $2,998.75 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $9.02 | $7.50 |
| 52 Week High | $11.09 | $18.30 |
Technical Indicators
Market Signals| Indicator | BHK | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 53.33 | 50.62 |
| Support Level | $9.53 | $16.61 |
| Resistance Level | $9.65 | $17.37 |
| Average True Range (ATR) | 0.07 | 0.70 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 76.32 | 38.17 |
Price Performance
Historical ComparisonAbout BHK Blackrock Core Bond Trust
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its managed assets in bonds that are investment-grade quality at the time of investment. The trust's investments will include a broad range of bonds, including corporate bonds, U.S. government and agency securities and mortgage-related securities.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.